ClinicalTrials.gg
CompletedNCT01811953Updated Jul 27, 2015Results posted

Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

A Phase 1 interventional study of Empagliflozin and Metformin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-27.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Bioequivalence of an empagliflozin/metformin (FDC) tablet compared with single tablets of two strength of empagliflozin and metformin (Part I) under fasted and under fed conditions and bioequivalence of empagliflozin/metformin (FDC) tablet compared with single tablets empagliflozin and metformin under fed conditions (Part II).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects

Exclusion criteria

Exclusion criteria:

  1. Any relevant deviation from healthy conditions
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    1 Empagliflozin/Metformin (T)

    fixed-dose-combination tablet, oral with 240 ml water under fasted conditions

    Drug: Empagliflozin/Metformin

  • Experimental
    2 Empagliflozin/Metformin (T)

    fixed-dose-combination tablet, oral with 240 ml water under fed conditions

    Drug: Empagliflozin/Metformin

  • Experimental
    3 Empagliflozin + Metformin (R)

    tablets, oral with 240 ml water under fasted conditions

    Drug: Empagliflozin · Drug: Metformin

  • Experimental
    4 Empagliflozin + Metformin (R)

    tablets, oral with 240 ml water under fed conditions

    Drug: Empagliflozin · Drug: Metformin

  • Experimental
    5 Empagliflozin/Metformin (T)

    fixed-dose-combination tablet, oral with 240 ml water under fed conditions

    Drug: Empagliflozin/Metformin

  • Experimental
    6 Empagliflozin + Metformin (R)

    tablets, oral with 240 ml water under fed conditions

    Drug: Empagliflozin · Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Empagliflozin

    AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Empagliflozin

    Time frame: 1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  2. Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Metformin

    AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Metformin

    Time frame: 1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  3. Maximum Measured Concentration of the Analyte in Plasma, Empagliflozin

    Cmax: maximum measured concentration of the analyte in plasma for Empagliflozin

    Time frame: 1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  4. Maximum Measured Concentration of the Analyte in Plasma, Metformin

    Cmax: maximum measured concentration of the analyte in plasma for Metformin

    Time frame: 1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

Secondary outcomes

  1. Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Empagliflozin

    AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Empagliflozin

    Time frame: 1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  2. Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Metformin

    AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Metformin

    Time frame: 1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

07

Results

Posted Jul 27, 2015

Participant flow

Participant flow — Overall Study
MilestoneEmp/Met Fasted / Emp+Met Fasted / Emp/Met Fed / Emp+Met FedEmp/Met Fed / Emp+Met Fed / Emp/Met Fasted / Emp+Met FastedEmp+Met Fasted / Emp/Met Fasted / Emp+Met Fed / Emp/Met FedEmp+Met Fed / Emp/Met Fed / Emp+Met Fasted / Emp/Met FastedLow Dose Emp: Emp/Met / Emp+MetLow Dose Emp: Emp+Met / Emp/Met
Started66661212
Completed66651111
Not completed000111
Withdrew: Adverse event000101
Withdrew: Protocol violation000010

Outcome measures

PrimaryArea Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Empagliflozin

AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Empagliflozin

Time frame:
1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Empagliflozin
nmol*h/L1 Empagliflozin/Metformin (T)2 Empagliflozin/Metformin (T)3 Empagliflozin + Metformin (R)4 Empagliflozin + Metformin (R)5 Empagliflozin/Metformin (T)6 Empagliflozin + Metformin (R)
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Empagliflozin2810 ± 19.32580 ± 20.42760 ± 20.02570 ± 20.7988 ± 16.2927 ± 18.0
Statistical analysis
  • 1 Empagliflozin/Metformin (T) vs 3 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 102.55 · 90% CI 99.531 to 105.653The geometric mean ratio was calculated as the geometric mean of '1 Empagliflozin/Metformin (T)' divided by the geometric mean of '3 Empagliflozin + Metformin (R)'.
  • 2 Empagliflozin/Metformin (T) vs 4 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 98.88 · 90% CI 94.879 to 103.059The geometric mean ratio was calculated as the geometric mean of '2 Empagliflozin/Metformin (T)' divided by the geometric mean of '4 Empagliflozin + Metformin (R)'.
  • 5 Empagliflozin/Metformin (T) vs 6 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 106.00 · 90% CI 102.728 to 109.386The geometric mean ratio was calculated as the geometric mean of '5 Empagliflozin/Metformin (T)' divided by the geometric mean of '6 Empagliflozin + Metformin (R)'.
PrimaryArea Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Metformin

AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Metformin

Time frame:
1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Metformin
ng*h/mL1 Empagliflozin/Metformin (T)2 Empagliflozin/Metformin (T)3 Empagliflozin + Metformin (R)4 Empagliflozin + Metformin (R)5 Empagliflozin/Metformin (T)6 Empagliflozin + Metformin (R)
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Metformin10400 ± 23.09220 ± 26.411000 ± 26.89140 ± 22.99080 ± 32.79060 ± 26.7
Statistical analysis
  • 1 Empagliflozin/Metformin (T) vs 3 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 96.13 · 90% CI 91.25 to 101.26The geometric mean ratio was calculated as the geometric mean of '1 Empagliflozin/Metformin (T)' divided by the geometric mean of '3 Empagliflozin + Metformin (R)'.
  • 2 Empagliflozin/Metformin (T) vs 4 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 99.34 · 90% CI 92.56 to 106.62The geometric mean ratio was calculated as the geometric mean of '2 Empagliflozin/Metformin (T)' divided by the geometric mean of '4 Empagliflozin + Metformin (R)'.
  • 5 Empagliflozin/Metformin (T) vs 6 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean difference: 100.81 · 90% CI 95.74 to 106.14The geometric mean ratio was calculated as the geometric mean of '5 Empagliflozin/Metformin (T)' divided by the geometric mean of '6 Empagliflozin + Metformin (R)'.
SecondaryArea Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Empagliflozin

AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Empagliflozin

Time frame:
1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Empagliflozin
nmol*h/L1 Empagliflozin/Metformin (T)2 Empagliflozin/Metformin (T)3 Empagliflozin + Metformin (R)4 Empagliflozin + Metformin (R)5 Empagliflozin/Metformin (T)6 Empagliflozin + Metformin (R)
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Empagliflozin2770 ± 19.22530 ± 20.12720 ± 20.02510 ± 20.2962 ± 16.3903 ± 18.2
Statistical analysis
  • 1 Empagliflozin/Metformin (T) vs 3 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 102.33 · 90% CI 99.315 to 105.430The geometric mean ratio was calculated as the geometric mean of '1 Empagliflozin/Metformin (T)' divided by the geometric mean of '3 Empagliflozin + Metformin (R)'.
  • 2 Empagliflozin/Metformin (T) vs 4 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 98.82 · 90% CI 94.784 to 103.037The geometric mean ratio was calculated as the geometric mean of '2 Empagliflozin/Metformin (T)' divided by the geometric mean of '4 Empagliflozin + Metformin (R)'.
  • 5 Empagliflozin/Metformin (T) vs 6 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 105.98 · 90% CI 102.730 to 109.329The geometric mean ratio was calculated as the geometric mean of '5 Empagliflozin/Metformin (T)' divided by the geometric mean of '6 Empagliflozin + Metformin (R)'.
PrimaryMaximum Measured Concentration of the Analyte in Plasma, Empagliflozin

Cmax: maximum measured concentration of the analyte in plasma for Empagliflozin

Time frame:
1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol/L
Maximum Measured Concentration of the Analyte in Plasma, Empagliflozin
nmol/L1 Empagliflozin/Metformin (T)2 Empagliflozin/Metformin (T)3 Empagliflozin + Metformin (R)4 Empagliflozin + Metformin (R)5 Empagliflozin/Metformin (T)6 Empagliflozin + Metformin (R)
Maximum Measured Concentration of the Analyte in Plasma, Empagliflozin379 ± 23.7276 ± 24.8375 ± 27.3258 ± 28.5108 ± 16.9103 ± 14.5
Statistical analysis
  • 1 Empagliflozin/Metformin (T) vs 3 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 102.12 · 90% CI 96.255 to 108.351The geometric mean ratio was calculated as the geometric mean of '1 Empagliflozin/Metformin (T)' divided by the geometric mean of '3 Empagliflozin + Metformin (R)'.
  • 2 Empagliflozin/Metformin (T) vs 4 Empagliflozin + Metformin (R) · ANOVA · p = 0.0082 · Geometric mean ratio: 106.52 · 90% CI 95.863 to 118.353The geometric mean ratio was calculated as the geometric mean of '2 Empagliflozin/Metformin (T)' divided by the geometric mean of '4 Empagliflozin + Metformin (R)'.
  • 5 Empagliflozin/Metformin (T) vs 6 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 104.352 · 90% CI 99.152 to 110.224The geometric mean ratio was calculated as the geometric mean of '5 Empagliflozin/Metformin (T)' divided by the geometric mean of '6 Empagliflozin + Metformin (R)'.
PrimaryMaximum Measured Concentration of the Analyte in Plasma, Metformin

Cmax: maximum measured concentration of the analyte in plasma for Metformin

Time frame:
1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng/mL
Maximum Measured Concentration of the Analyte in Plasma, Metformin
ng/mL1 Empagliflozin/Metformin (T)2 Empagliflozin/Metformin (T)3 Empagliflozin + Metformin (R)4 Empagliflozin + Metformin (R)5 Empagliflozin/Metformin (T)6 Empagliflozin + Metformin (R)
Maximum Measured Concentration of the Analyte in Plasma, Metformin1580 ± 26.91160 ± 17.81680 ± 25.81180 ± 21.21180 ± 23.81150 ± 24.8
Statistical analysis
  • 1 Empagliflozin/Metformin (T) vs 3 Empagliflozin + Metformin (R) · ANOVA · p = 0.0001 · Geometric mean ratio: 94.87 · 90% CI 88.931 to 101.210The geometric mean ratio was calculated as the geometric mean of '1 Empagliflozin/Metformin (T)' divided by the geometric mean of '3 Empagliflozin + Metformin (R)'.
  • 2 Empagliflozin/Metformin (T) vs 4 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 97.97 · 90% CI 92.339 to 103.935The geometric mean ratio was calculated as the geometric mean of '2 Empagliflozin/Metformin (T)' divided by the geometric mean of '4 Empagliflozin + Metformin (R)'.
  • 5 Empagliflozin/Metformin (T) vs 6 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 102.95 · 90% CI 97.166 to 109.082The geometric mean ratio was calculated as the geometric mean of '5 Empagliflozin/Metformin (T)' divided by the geometric mean of '6 Empagliflozin + Metformin (R)'.
SecondaryArea Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Metformin

AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Metformin

Time frame:
1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Metformin
ng*h/mL1 Empagliflozin/Metformin (T)2 Empagliflozin/Metformin (T)3 Empagliflozin + Metformin (R)4 Empagliflozin + Metformin (R)5 Empagliflozin/Metformin (T)6 Empagliflozin + Metformin (R)
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Metformin10100 ± 21.38960 ± 24.510700 ± 24.18930 ± 22.58870 ± 30.88850 ± 26.3
Statistical analysis
  • 1 Empagliflozin/Metformin (T) vs 3 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 94.89 · 90% CI 89.80 to 100.26The geometric mean ratio was calculated as the geometric mean of '1 Empagliflozin/Metformin (T)' divided by the geometric mean of '3 Empagliflozin + Metformin (R)'.
  • 2 Empagliflozin/Metformin (T) vs 4 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 99.31 · 90% CI 92.14 to 107.03The geometric mean ratio was calculated as the geometric mean of '2 Empagliflozin/Metformin (T)' divided by the geometric mean of '4 Empagliflozin + Metformin (R)'.
  • 5 Empagliflozin/Metformin (T) vs 6 Empagliflozin + Metformin (R) · ANOVA · p = <0.0001 · Geometric mean ratio: 100.74 · 90% CI 95.77 to 105.96The geometric mean ratio was calculated as the geometric mean of '5 Empagliflozin/Metformin (T)' divided by the geometric mean of '6 Empagliflozin + Metformin (R)'.

Adverse events

Collected over From first trial medication intake until next intake or the end-of-trial visit, 10 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1 Empagliflozin/Metformin (T)—0/23 (0%)6/23 (26.1%)
2 Empagliflozin/Metformin (T)—0/24 (0%)6/24 (25%)
3 Empagliflozin + Metformin (R)—0/24 (0%)4/24 (16.7%)
4 Empagliflozin + Metformin (R)—0/24 (0%)6/24 (25%)
5 Empagliflozin/Metformin (T)—0/23 (0%)9/23 (39.1%)
6 Empagliflozin + Metformin (R)—0/23 (0%)10/23 (43.5%)
Most frequent other events
Most frequent other events
Event1 Empagliflozin/Metformin (T)2 Empagliflozin/Metformin (T)3 Empagliflozin + Metformin (R)4 Empagliflozin + Metformin (R)5 Empagliflozin/Metformin (T)6 Empagliflozin + Metformin (R)
DiarrhoeaGastrointestinal disorders2/233/241/244/244/236/23
HeadacheNervous system disorders4/230/242/241/243/234/23
NauseaGastrointestinal disorders1/230/241/240/243/231/23
VomitingGastrointestinal disorders1/231/240/241/242/230/23
NasopharyngitisInfections and infestations1/232/240/241/240/230/23

Baseline characteristics

Treated Set (TS): includes all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment

Age, Continuous
Age, Continuous(years)Emp/Met Fasted / Emp+Met Fasted / Emp/Met Fed / Emp+Met FedEmp/Met Fed / Emp+Met Fed / Emp/Met Fasted / Emp+Met FastedEmp+Met Fasted / Emp/Met Fasted / Emp+Met Fed / Emp/Met FedEmp+Met Fed / Emp/Met Fed / Emp+Met Fasted / Emp/Met FastedLow Dose Emp: Emp/Met / Emp+MetLow Dose Emp: Emp+Met / Emp/MetTotal
Mean33.5 ± 6.726.5 ± 9.728.5 ± 9.533.2 ± 7.132.8 ± 9.832.3 ± 9.631.5 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Emp/Met Fasted / Emp+Met Fasted / Emp/Met Fed / Emp+Met FedEmp/Met Fed / Emp+Met Fed / Emp/Met Fasted / Emp+Met FastedEmp+Met Fasted / Emp/Met Fasted / Emp+Met Fed / Emp/Met FedEmp+Met Fed / Emp/Met Fed / Emp+Met Fasted / Emp/Met FastedLow Dose Emp: Emp/Met / Emp+MetLow Dose Emp: Emp+Met / Emp/MetTotal
Female33147725
Male33525523
08

Study locations

1 site
  • 1276.8.1 Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2013
First posted
Mar 15, 2013
Start
Mar 2013
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Jul 27, 2015
Last update
Jul 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01811953
Responsible party
Sponsor
First posted
Mar 15, 2013
Start date
Mar 2013
Primary completion
May 2013
Completion
May 2013
Results posted
Jul 27, 2015
Last update
Jul 27, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Metformin

Start the discussion